Drug Trial Radar · NCT05970640
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Aug 14, 2023
Primary completion
Oct 31, 2024
Study completion Nov 7, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease can tolerate. Participants are divided into 4 groups of equal size randomly, which means by chance. Different doses of BI 3006337 are given to participants in each group. Participants in each group receive an injection of either BI 3006337 or placebo once a week. Placebo injections look like BI 3006337 injections but do not contain any medicine. Participants are in the study for about 4 months. During this time, they visit the study site 18 times. Three of the visits include overnight stays at the study site. The doctors check the health of the participants and note any health problems that could have been caused by BI 3006337.
Conditions
- Non-alcoholic Fatty Liver Disease
- Obesity
Interventions
BI 3006337Drug
Subject with overweight/obesity and steatosis received subcutaneous solution once weekly.
Placebo matching BI 3006337Drug
Subject with overweight/obesity and steatosis received subcutaneous solution once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Drug-related Adverse Events (AEs)Time frame: From drug administration of BI 3006337 until end of the treatment, up to 99 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Velocity Clinical Research-Chula Vista
Chula Vista, California
Velocity Clinical Research-La Mesa-69117
La Mesa, California
Catalina Research Institute, LLC-Montclair-49051
Montclair, California
Accel Research Sites-Deland-67606
DeLand, Florida
Floridian Clinical Research-Miami Lakes-68368
Miami Lakes, Florida
iResearch Atlanta
Decatur, Georgia
Centricity Research-Columbus-68879
Columbus, Ohio
AMR Knoxville
Knoxville, Tennessee
The Liver Institute at Methodist Dallas
Dallas, Texas
American Research Corporation at the Texas Liver Institute
San Antonio, Texas
Endeavor Clinical Trials
San Antonio, Texas
Velocity Clinical Research-West Jordan-69043
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.